Bio-Gene Technology (BGT.AX) Stock Price
Bio-Gene Technology Price
Over the last 11 years Bio-Gene Technology grew revenue by 119.1% annually, reaching 425,070.00 AUD. For Bio-Gene Technology, the net margin of -608.0% is up versus -3,827.3% a few years ago.
Bio-Gene Technology stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Bio-Gene Technology business model & stock analysis
Frequently asked questions about Bio-Gene Technology
Converted at the current exchange rate, the Bio-Gene Technology share trades at 0.01 EUR (0.01 AUD).
The revenue cannot currently be calculated for Bio-Gene Technology.
The profit of Bio-Gene Technology is -2.33 M AUD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Bio-Gene Technology is currently -1.90. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Bio-Gene Technology stock.
The P/S cannot be calculated for Bio-Gene Technology currently.
The Eulerpool Quality Score for Bio-Gene Technology is 2/10.
The ISIN of Bio-Gene Technology is AU000000BGT8. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Bio-Gene Technology is BGT.AX. The ticker symbol is used to trade Bio-Gene Technology shares on the stock exchange.
Bio-Gene Technology stock
Bio-Gene Technology Peer Group
Bio-Gene Technology FIGI
All fundamentals and in-depth analysis of Bio-Gene Technology
Our stock analysis for Bio-Gene Technology stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bio-Gene Technology. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.